Abstract 96P
Background
Determination of MMR functioning in EC is recommended by international guidelines. Its deficiency leads to MSI with intermediate prognosis. Available data have shown a reasonable concordance between IHC-MMR and NGS-MSI. We aim at evaluating the sensitivity and specificity of NGS-MSI obtained from a comprehensive cancer genome profiling (CGP) assay compared with the gold standard IHC-MMR.
Methods
Selected EC patients were profiled using TruSight Oncology500 High Throughput solution. MSI status was determined by 130 noncoding homopolymer regions and at least 40 sites were assessed to provide a score (threshold MSI high>20). IHC-MMR evaluation was collected from standard pathology report.
Results
From March 2022 to May 2023, 404 EC were enrolled. NGS-MSI evaluation was available for 354 (87%; see table). Cohort characteristics are reported in the table. Sensitivity and specificity of NGS-MSI testing compared to IHC-MMR were 99% (n=223/224) and 52% (n= 68/130) respectively, with a concordance rate of 82% (Cohen Kappa = 0.58; p < .0001). The positive predictive value of NGS-MSI was 78% (n=223/285), while the negative predictive value was 99% (n= 68/69). Among the 62 misclassified cases, 19 were MSH6 + MSH2 deficient, 42 MLH1 + PMS2 deficient and 1 was deficient for PMS2, MLH1 and MSH6. 38 MLH1 + PMS2 deficient patients were addressed to MLH1 promoter methylation analysis: results are available for 15 cases (11 hypermethylated, 2 partially hypermethylated). All 19 MSH6 + MSH2 deficient were addressed to genetic counselling: results are available only for 3 patient (1 displaying a MSH2 pathogenic variant). Table: 96P
Characteristics | Cohort (N = 354) | ||
Histotype, n (%) | |||
Endometrioid | 307 (87%) | ||
Serous carcinoma | 18 (5%) | ||
Others | 29 (8%) | ||
FIGO Stage 2019*, n (%) | |||
I-II | 149 (93%) | ||
III-IV | 25 (7%) | ||
MSI status, n (%) | |||
MSI | 69 (19%) | ||
MSS | 285 (81%) | ||
MMR IHC status, n (%) | |||
pMMR | 224 (63%) | ||
dMMR | 130 (37%) |
Conclusions
A moderate concordance between IHC-MMR and NGS-MSI was reported in our study. However, given the approval of immunotherapy in several settings it is important to further characterize the misclassified cases.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Nero: Non-Financial Interests, Personal, Other: Illumina. D. Lorusso: Financial Interests, Personal, Invited Speaker: Clovis, GSK, MSD, AZ, PharmaMar.G. Scambia: Financial Interests, Personal, Invited Speaker: MSD, Clovis, Tesaro, J&J. All other authors have declared no conflicts of interest.
Resources from the same session
62P - Role of IL6 (C-174G) polymorphism in the development of cervical intraepithelial neoplasia
Presenter: Tatyana Abakumova
Session: Cocktail & Poster Display session
Resources:
Abstract
63P - The impact of disruption of melatonin secretion on the structural-functional changes of the microbiome and the role of the melatonin-microbiome axis in the initiation of carcinogenesis
Presenter: Alexandre Tavartkiladze
Session: Cocktail & Poster Display session
Resources:
Abstract
64P - Acidosis induces ferroptosis of breast cancer via ZFAND5/SLC3A2 axis with the synergistic effect of metformin and facilitates M1 macrophage polarization
Presenter: Hanchu Xiong
Session: Cocktail & Poster Display session
Resources:
Abstract
65P - Transmembrane distribution of phosphatidylethanolamine in plasma membrane of ovarian cancer cells under conditions mimicking tumor microenvironment
Presenter: Darya Savenkova
Session: Cocktail & Poster Display session
Resources:
Abstract
66P - Metabolic regulation of GMP- and MDP-derived macrophages in glioblastoma
Presenter: Liam Wilson
Session: Cocktail & Poster Display session
Resources:
Abstract
67P - Inflammation status and sarcopenia synergistically impact outcomes in cancer patients (pt) treated with ImmunOtherapy (IO) within the framework of a Molecular Pre-screening program (MP) and a spEcial Medication (ME) program
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
68P - The role of systemic reprogramming of GMPs in improving outcomes in glioblastoma
Presenter: Aline Atallah
Session: Cocktail & Poster Display session
Resources:
Abstract
69P - Integrated OMIC analysis reveals arginine and proline metabolism plays critical role in hypoxia-induced oral squamous cell carcinoma
Presenter: Avinash Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
70P - Individualising methotrexate dose based on MTHFR gene polymorphisms in acute lymphoblastic leukemia
Presenter: Meher Konatam
Session: Cocktail & Poster Display session
Resources:
Abstract
71P - Single nucleotide polymorphisms in the folate metabolic pathway genes and global DNA methylation in ovarian cancer
Presenter: Sandro Surmava
Session: Cocktail & Poster Display session
Resources:
Abstract